ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on May 3, 2024. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "NDRA". The report addresses a regulatory notification regarding the Company's continued listing status.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on a listing compliance issue related to the Company's stock price.
Material Changes and Events
On May 3, 2024, the Company received a notification from Nasdaq stating that its common stock no longer meets the Minimum Bid Price Requirement under Nasdaq Marketplace Rule 5550(a)(2). This deficiency occurred because the closing bid price was below $1.00 for 30 consecutive trading days. The notification has no immediate effect on the listing of the stock.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days, until October 30, 2024, to regain compliance.
- Compliance Criteria: To regain compliance, the bid price must close at or above $1.00 per share for a minimum of 10 consecutive business days before the deadline.
- Secondary Compliance Period: If the Company fails to meet the requirement by October 30, 2024, it may be eligible for an additional 180-day period. This requires meeting all other initial listing standards (except bid price) and providing written notice of intent to cure, potentially via a reverse stock split.
- Delisting Risk: If the Company cannot cure the deficiency or is deemed ineligible for an extension, Nasdaq may initiate delisting proceedings. The Company may appeal such a determination, though success is not assured.
- Management Action: The Company intends to actively monitor the bid price and consider available options to resolve the deficiency.
Key Facts for Investor Verification
- Verify the current closing bid price of NDRA stock to assess proximity to the $1.00 threshold.
- Monitor the Company's stock performance over the next 10 consecutive business days to determine if immediate compliance is achieved.
- Watch for future announcements regarding a potential reverse stock split if the initial 180-day period expires without compliance.
- Review the Company's ability to meet other Nasdaq initial listing standards (e.g., market value of publicly held shares) in case a second compliance period is required.